Highly esteemed clinician-scientist, Dr Shom Goel, joins Peter Mac from the Dana-Farber Cancer Institute and Harvard Medical School in Boston, where he has spent the last 10 years breaking new ground in breast cancer research and treatment.

Dr Goel will lead a research group in the study of cell cycle biology in breast cancer, with a focus on the CDK4/6 pathway. His research uses state-of-the-art preclinical mouse models to answer questions that have a clear focus on translating lab results into improved clinical practice.

As a world-class doctor he will also continue in his clinical care duties as a medical oncologist in Peter Mac’s Breast Tumour stream, and lead the burgeoning collaboration between Peter Mac and the Dana-Farber, building programs that strengthen academic links between the two institutes.

Dr Goel brings with him a wealth of experience. He graduated from the University of Adelaide medical school in 2002 and received both the University Medal and Honours Alumni University Medal, awarded to the highest-ranked graduate across all faculties of the University. He completed clinical training in Internal Medicine in Sydney, receiving the Bryan Hudson Medal from the Royal Australasian College of Physicians, and completed his medical oncology fellowship in 2009.

Supported the WG Walker Fulbright Scholarship (awarded to Australia’s highest-ranked Fulbright Scholar each year), he relocated to Boston to conduct his doctoral research at the Massachusetts General Hospital. He was subsequently awarded a Young Investigator Award from the American Society of Clinical Oncology (ASCO), and was then appointed as a Goldfarb-Rudkin Fellow in Breast Oncology at Dana-Farber in 2009. He joined the faculty of the Dana-Farber and Harvard Medical School in 2012. He was also awarded the Dana-Farber’s inaugural J. Dirk Iglehart Fellowship in Breast Oncology.

His laboratory findings have been published in prestigious journals such as Nature and Cancer Cell, and his seminal results have translated directly from bench to the bedside through the opening of numerous international clinical trials. Dr Goel currently sits on a number of international advisory panels, leads several clinical trials, and oversees the translational studies for two global randomized studies of CDK4/6 inhibitors in breast cancer.

Peter Mac extends a warm welcome to Dr Goel.